A recent analyst survey indicates that despite safety concerns surrounding Sarepta’s Elevidys gene therapy, doctors are still prescribing it, particularly to ambulatory patients, showcasing confidence in its risk-benefit profile.
BMO Capital Markets’ survey of 30 physicians revealed that approximately 90% of them continue to prescribe Elevidys, focusing on ambulatory patients following regulatory scrutiny due to reported deaths in non-ambulatory individuals. Interestingly, over a quarter of surveyed doctors expressed willingness to administer Elevidys to younger and healthier patients, underscoring their belief in the therapy’s efficacy.
The favorable risk/benefit ratio of Elevidys in ambulatory patients, with over 760 treated individuals and zero deaths, has bolstered physicians’ confidence. Ambulatory patients, typically healthier and lighter, necessitate lower Elevidys doses compared to non-ambulatory patients, who are usually older and more advanced in their disease progression.
Elevidys, approved for ambulatory Duchenne muscular dystrophy patients aged four and above with confirmed DMD gene mutations, also holds potential for non-ambulatory patients under accelerated approval, pending confirmation of its benefits for full traditional approval by Sarepta.
The series of deaths linked to Elevidys, especially in non-ambulatory patients, resulted in regulatory actions, including a temporary halt in shipments by the FDA. Despite these setbacks, the therapy’s demand remains steady, with physicians collectively infusing patients post-resumption, signaling ongoing interest in Elevidys.
Sarepta’s stock performance reflects the impact of the safety concerns, with an 85% decline year-to-date. However, the recent resumption of Elevidys shipments and physicians’ continued prescription indicate a path to recovery for the company, albeit with some reservations among healthcare providers.
Physicians are cautiously optimistic about Elevidys’ safety enhancements, such as the proposed dosing guidelines involving the immunosuppressant sirolimus to mitigate liver enzyme elevation risks. The majority of surveyed doctors believe that these modifications will enhance the therapy’s safety profile, instilling further confidence in its use.
While the market environment has not witnessed deaths among ambulatory patients post-Elevidys resumption, half of the physicians indicated that any such occurrence would prompt them to pause prescriptions until updated safety information is available. This cautious approach underscores the importance of ongoing safety monitoring in gene therapy administration.
Looking ahead, Sarepta’s adherence to enhanced safety protocols and continuous monitoring of Elevidys’ real-world outcomes will be pivotal in sustaining physician confidence and patient trust. As the company navigates the aftermath of safety concerns, its ability to address regulatory expectations and healthcare provider feedback will be critical in shaping Elevidys’ future trajectory.
In conclusion, despite initial safety setbacks, Sarepta’s Elevidys gene therapy continues to garner support from physicians, especially in treating ambulatory Duchenne muscular dystrophy patients. The therapy’s resilience post-regulatory scrutiny underscores the importance of risk mitigation strategies and ongoing safety monitoring in advancing gene therapy innovation and adoption.
Takeaways:
– Physicians maintain confidence in Sarepta’s Elevidys gene therapy, particularly for ambulatory Duchenne muscular dystrophy patients.
– Ongoing safety enhancements and monitoring protocols are crucial for sustaining physician trust and patient safety in gene therapy administration.
– Sarepta’s response to regulatory expectations and healthcare provider feedback will be instrumental in shaping Elevidys’ future market performance and adoption.
Tags: regulatory, gene therapy
Read more on biospace.com